

Kure Cells, Inc.



Headquarters: Cleveland, Ohio (Affiliate in Riyadh; Global development footprint)

Sector: Healthcare/ Cell & Gene Therapy

Stage & Funding Type: Series B | Private

Problem:

CAR-T therapy remains inaccessible to >99% of eligible patients due to long manufacturing times, high costs, and safety limitations — despite its proven ability to transform outcomes for refractory cancer patients.

Solution:

Kure's **ultra-fast (<1-day) automated CAR-T manufacturing platform** delivers high-quality, patient-specific products at a fraction of current costs while improving efficacy, safety, and global scalability.

Market Opportunity:

Rapidly expanding multi-billion-dollar global CAR-T market projected to exceed \$30 B by 2030, with significant unmet demand in non-U.S. markets and autoimmune indications.

Traction:

Global partnerships (ex. KFSHRC) enabling accelerated approval pathways

- US FDA RMAT designation for lead program (UF-Kure19) – expedited development and review path
- Scientific recognition: Global ISCT Meeting Top Abstract Award; >\$2.5 M in NIH funding
- Phase 1/1b trial showed 88% complete remission in refractory patients with minimal toxicity
- Pipeline for solid tumor, blood cancer and autoimmune disease

Snapshot of Lead / Notable Investors:

Wa'ed (Ventures of Saudi Aramco), NantBio, Qomel

Team: David Wald (CEO), Sayer Alfuraydi (COO), Marcos de Lima (CMO)

Funding Ask: Seeking **\$30M** in late 2026 to complete international clinical trials and advance to commercial launch

Contact Information: David Wald, CEO – david@kure.ai

